Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Lycored Launches New Lumenato® Delivery Format, Offering Customers Expanded Product Opportunities


BRANCHBURG, N.J., May 22, 2024 /PRNewswire/ -- Lycored, the global leader in natural carotenoids for food, beverage, and dietary supplement products, just launched a new delivery format ? Lumenato® Emulsion ? for their proprietary extract, Lumenato. This will be Lycored's latest addition to their lineup of delivery formats for this ingestible skincare ingredient, providing Consumer Packaged Goods companies with expanded formulation opportunities.

Lycored

 

Lumenato is made of phytonutrients, like phytoene and phytofluene, and essential fatty acids that build a reservoir of goodness within the body; working from inside of the body out to support skin structure and protect collagen for improved elasticity, firmness, and more.1,2 This new liquid emulsion expands brands' opportunities to leverage the versatile benefits of Lumenato in new applications, including liquid and shot-style beverages, such as wellness shots.

Backed by science and formulated with results and functionality in mind, Lumenato Emulsion brings Lycored's customers a free-flowing format that leaves no visible particles and can be handled with ease. To assess Lumenato emulsion's performance over time, a 9-month shelf-life stability study helped determine the active's presence by measuring levels of carotenoids, phytoene and phytofluene, while stability was determined by evaluating beverage color. Results established it as a reliable, shelf-stable format that effectively supports beauty from within for consumers. Whether used stand-alone or paired with other ingredients like collagen and ceramides for synergistic effects, Lumenato presents diverse opportunities for brands in the growing wellness beverage category.

Lumenato comes in two other formulations: Lumenato Starch Beadlets, used for gummies, dry beverages, and capsules, and Lumenato Extract, used for soft gels, nutritional bars, chocolates, and ice cream. Caroline Schroeder, Global Head of Marketing, states, "Lumenato is a star skincare ingredient that strengthens skin from the inside out, supporting beauty from within. With our latest Lumenato emulsion delivery format, brands can develop more nourishing, top-of-the-line, and shelf-stable products to draw in and delight their consumers."

About Lycored?
Lycored is an international company at the forefront of discovering the beauty within by combining nature's goodness with cutting edge science to deliver a sensory journey that impacts wellbeing. Established in 1995 in Israel, Lycored is the global leader in natural carotenoids for food, beverage and dietary supplement products. For more information visit www.lycored.com.?? 

Contact?
Katie Hill?
Padilla?
+1-480-285-8148?
[email protected] 

  1. Tarshish et al. 2021? 
  2. Tarshish et al. 2023 

Logo - https://mma.prnewswire.com/media/2418971/Lycored_Logo.jpg


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: